Ohio University

A Novel and Efficacious Therapy for Human Liver Cancer

Overview

Human liver cancer is one of the most pharmacologically challenging cancer types with almost 700,000 (40,710 in the US) new diagnoses and 600,000 (28,920 in US) deaths worldwide, annually. Current approved treatments are limited to surgery (liver transplant, laparoscopy), radiation (brachytherapy), and a single small molecule (sorafenib). Surgery and radiation are limited to early diagnoses, leaving sorafenib as the only treatment option for advanced and metastatic cases of liver cancer. Sorafenib has a high effective dose (>1500mg/daily) and multiple undesirable side effects (cardiovascular complications, internal bleeding). Even with treatment, there is still a high degree of disease recurrence (>50%). Therefore, the field of human liver cancer has a standing order for new, effective drug candidates.

 

Image of a Graph
(a) EC50 (effective concentration for 50% reduction in cell viability) of full length human FSP27 against several human cancer c
human fibroblast
(b) FSP27-fl has very low toxicity against non-cancerous human fibroblast cells showing specificity for cancer cells over normal
Image of a graph
(c) FSP27-fl augments sorafenib and doxorubicin effects significantly even at sub-EC50 doses when used as an adjuvant therapy in
Image of a graph
(d) A unique 20-amino acid peptide of human FSP27 (FSP27-p20), shows increased potency over full length FSP27, against human liv

  •  

Patent Status

Published patent application: WO 2019/060245

OU Ref: 18001 View PDF